| Previous close | 0.7500 |
| Open | 0.7600 |
| Bid | 0.8300 x 0 |
| Ask | 0.7800 x 0 |
| Day's range | 0.7600 - 0.7950 |
| 52-week range | 0.2550 - 1.3511 |
| Volume | |
| Avg. volume | 9,747,295 |
| Market cap | 884.05M |
| Beta (5Y monthly) | 2.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
- Insider Monkey
Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript
Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript February 29, 2024 Mesoblast Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Silviu Itescu: Good morning, good afternoon to Mesoblast’s Financial Results and Operational Update for the Half Year ended December 31, […]
- Simply Wall St.
Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag
Mesoblast ( ASX:MSB ) First Half 2024 Results Key Financial Results Net loss: US$32.5m (loss narrowed by 21% from 1H...
© 2024 Yahoo. All rights reserved.